Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

Not Applicable

Completed

• Conditions: Meibomian Gland Dysfunction
• Interventions: Drug: Treatment of Meibomian gland dysfunction

• Registration Number: NCT02618304
• Lead Sponsor: Yonsei University

Brief Summary

In this study, investigator aim to evaluate the changes of tear-film lipid layer thickness and ocular aberration after treatment of meibomian gland dysfunction. In case of stage 3 or 4 meibomian gland dysfunction, participants will be treated using conventional treatment modalities. Before treatment and after 1 and 2 months of treatment, a variety of ophthalmic examination, tear-film lipid layer thickness, and ocular aberration are going to measured and compared.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04-20
• Study First Submitted: 2015-11-18
• Study First Submitted QC: 2015-11-27
• Study First Posted: 2015-12-01
• Primary Completion: 2016-02-19
• Study Completion: 2016-02-19
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-08
• Last Update Posted: 2019-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1. age over 19 years old, with moderate to severe Meibomian gland dysfunction.

Read More

Exclusion Criteria

1. patients with history of previous ocular or intraocular surgery
2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease
3. history of intolerance or hypersensitivity to any component of the study medications
4. wearing contact lenses during the study period, presence of current punctal occlusion
5. pregnancy, lactating women, and children

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
moderate to severe meibomian gland dysfunction	Treatment of Meibomian gland dysfunction	-

Primary Outcome Measures

Name	Time	Method
Changes of tear-film lipid layer thickness after treatment of meibomian gland dysfunction	1 and 2 months after treatment of meibomian gland dysfunction
Changes of ocular aberration after treatment of meibomian gland dysfunction	1 and 2 months after treatment of meibomian gland dysfunction	ocular parameters measured by Ray-tracing wavefront aberrometers (i-Trace, Tracey technologies , Texas ,USA)

Secondary Outcome Measures

Name	Time	Method
Corneal erosion grade(oxford score)	1 and 2 months after treatment of meibomian gland dysfunction
OSDI(ocular surface disease index)	1 and 2 months after treatment of meibomian gland dysfunction
Meibomian gland abnormality	1 and 2 months after treatment of meibomian gland dysfunction	measured by physiological parameter (score 0,1,2,3,4)
Meibomian quality	1 and 2 months after treatment of meibomian gland dysfunction	measured by physiological parameter (score 0,1,2,3,4)
BUT(tear break-up time)	1 and 2 months after treatment of meibomian gland dysfunction

Trial Locations

Locations (1)

Department of Ophthalmology, Yonsei Univeristy College of Medicine; 🇰🇷 Seoul, Korea, Republic of